Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

201. Antiplatelet and anticoagulant treatments for unstable angina/non?ST elevation myocardial infarction

Antiplatelet and anticoagulant treatments for unstable angina/non?ST elevation myocardial infarction Antiplatelet and anticoagulant treatments for unstable angina/non–ST elevation myocardial infarction Antiplatelet and anticoagulant treatments for unstable angina/non–ST elevation myocardial infarction Melloni C, Jones WS, Washam JB, Hasselblad V, Mayer SB, Halim S, Subherwal S, Alexander K, Kong DF, Heidenfelder BL, Irvine RJ, Wing L, Dolor RJ Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Melloni C, Jones WS, Washam JB, Hasselblad V, Mayer SB, Halim S, Subherwal S, Alexander K, Kong DF, Heidenfelder BL, Irvine RJ, Wing L, Dolor RJ. Antiplatelet and anticoagulant treatments for unstable angina/non–ST elevation myocardial infarction. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 129

Health Technology Assessment (HTA) Database.2014

202. Anticoagulant treatment for subsegmental pulmonary embolism.

Anticoagulant treatment for subsegmental pulmonary embolism. BACKGROUND: Acute pulmonary embolism (PE) is a common cause of death, accounting for 50,000 to 200,000 deaths annually. It is the third most common cause of mortality among the cardiovascular diseases, after coronary artery disease and stroke.The advent of multi-detector computed tomographic pulmonary angiography (CTPA) has allowed better assessment of PE regarding visualisation of the peripheral pulmonary arteries, increasing its (...) by diagnostic imaging performed for other reasons (for example routine CT for cancer staging in oncologic patients).Traditionally, all PEs are anticoagulated in a similar manner independent of the location, number and size of the thrombi. It has been suggested that many patients with SSPE may be treated without benefit, increasing adverse events by possible unnecessary use of anticoagulants.Patients with isolated SSPE or incidental PE may have a more benign clinical presentation compared with those

Cochrane2014

203. Anticoagulation in atrial fibrillation.

Anticoagulation in atrial fibrillation. Atrial fibrillation increases the risk of stroke, which is a leading cause of death and disability worldwide. The use of oral anticoagulation in patients with atrial fibrillation at moderate or high risk of stroke, estimated by established criteria, improves outcomes. However, to ensure that the benefits exceed the risks of bleeding, appropriate patient selection is essential. Vitamin K antagonism has been the mainstay of treatment; however, newer drugs (...) with novel mechanisms are also available. These novel oral anticoagulants (direct thrombin inhibitors and factor Xa inhibitors) obviate many of warfarin's shortcomings, and they have demonstrated safety and efficacy in large randomized trials of patients with non-valvular atrial fibrillation. However, the management of patients taking warfarin or novel agents remains a clinical challenge. There are several important considerations when selecting anticoagulant therapy for patients with atrial fibrillation

BMJ2014

205. An antidote on the horizon? An update on the progress toward achieving reversibility for the new oral anticoagulants

An antidote on the horizon? An update on the progress toward achieving reversibility for the new oral anticoagulants An antidote on the horizon? An update on the progress toward achieving reversibility for the new oral anticoagulants | Clinical Correlations An antidote on the horizon? An update on the progress toward achieving reversibility for the new oral anticoagulants February 21, 2014 By Gabriel Schneider, MD Peer Reviewed The new oral anticoagulants (NOACs) are an appealing alternative (...) frozen plasma (FFP) and prothrombin complex concentrate (PCC) can be used to quickly replace the vitamin K–dependent clotting proteins; of note, four-factor PCC (Kcentra, Octaplex)contains significant amounts of factors II, VII, IX, and X, whereas three-factor . [8] When it comes to the NOACs, transfusions are unlikely to be effective since the problem is not a deficit of . [9] The following agents are currently being investigated as possible new anticoagulation antidotes: PRT064445 This protein

Clinical Correlations2014

206. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation

The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation 24055744 2013 12 06 2014 02 17 2014 06 25 1558-3597 62 23 2013 Dec 10 Journal of the American College of Cardiology J. Am. Coll. Cardiol. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. 2199-204 10.1016/j.jacc.2013.08.1623 S0735-1097 (...) heart failure, hypertension, 75 years of age and older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, 65 to 74 years of age, female) in anticoagulated atrial fibrillation (AF) patients. The CHADS2 and CHA2DS2-VASc scores are well-validated stroke risk prediction scores for AF, but are also associated with increased bleeding and mortality. We recruited 1,370 consecutive AF patients (49% male; median age, 76 years) receiving oral anticoagulation therapy from our

EvidenceUpdates2014

207. Reduced anticoagulation after mechanical aortic valve replacement: Interim results from the Prospective Randomized On-X Valve Anticoagulation Clinical Trial randomized Food and Drug Administration investigational device exemption trial

Reduced anticoagulation after mechanical aortic valve replacement: Interim results from the Prospective Randomized On-X Valve Anticoagulation Clinical Trial randomized Food and Drug Administration investigational device exemption trial 24512654 2014 03 17 2014 05 12 2015 01 12 1097-685X 147 4 2014 Apr The Journal of thoracic and cardiovascular surgery J. Thorac. Cardiovasc. Surg. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized (...) on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. 1202-1210; discussion 1210-1 10.1016/j.jtcvs.2014.01.004 S0022-5223(14)00010-5 Under Food and Drug Administration investigational device exemption, the Prospective Randomized On-X Anticoagulation Clinical Trial (PROACT) has been testing the safety of less aggressive anticoagulation than recommended by the American College of Cardiology/American Heart Association guidelines after

EvidenceUpdates2014

208. Risk factors to consider for extended anticoagulant therapy: a review of guidelines

Risk factors to consider for extended anticoagulant therapy: a review of guidelines Risk factors to consider for extended anticoagulant therapy: a review of guidelines Risk factors to consider for extended anticoagulant therapy: a review of guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Risk factors to consider (...) for extended anticoagulant therapy: a review of guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions There was one evidence-based guideline identified that evaluated risks and benefits of extended duration anticoagulation. The guidelines state that decision to extend anticoagulation therapy beyond the standard three month treatment should consider the patients risk of recurrent VTE, major bleeding

Health Technology Assessment (HTA) Database.2014

209. Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness

Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT (...) and PE: a review of the clinical and cost-effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs

Health Technology Assessment (HTA) Database.2014

210. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Ruff CT, Giugliano RP, Braunwald E (...) , Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM CRD summary This review concluded that new oral anticoagulants offered significant reductions in stroke, intracranial haemorrhage, and mortality, compared with warfarin, with a similar risk of major bleeding and an increased risk of gastrointestinal bleeding. Despite shortcomings in the reporting, these conclusions are likely to be reliable. Authors' objectives To assess the efficacy and safety

DARE.2014

211. Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis

Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis Measurement of non-Coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology - Kitchen - 2014 - British Journal of Haematology - Wiley Online Library By continuing to browse this site you agree to us using cookies as described in Navigate this article Previous article in issue: Progress and prospects for engineered T cell therapies Next (...) healthcare professionals with clear guidance on the clinically important issues regarding the laboratory assessment of currently used non-coumarin anticoagulants and their impact on laboratory tests of haemostasis. A short summary of the effects of rivaroxaban and dabigatran on routine coagulation screens and assessment of anticoagulation intensity on behalf of the BCSH (Baglin et al , ) and international recommendations related to measurement of oral direct inhibitors (Baglin et al , ) have recently

British Committee for Standards in Haematology2014

212. Anticoagulation and Antiplatelet Therapy in Urologic Practice

Anticoagulation and Antiplatelet Therapy in Urologic Practice American Urological Association - AUA - Home American Urological Association - AUA - Home advertisement Toggle navigation About Us Membership About AUA AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Non-Neoplastic Lesions Cystitis Histoanatomic Abnormalities/Malformations Non-invasive Urothelial Neoplasms Invasive

American Urological Association2014

213. Randomised clinical trial: Novel anticoagulants in patients with mechanical heart valves

Randomised clinical trial: Novel anticoagulants in patients with mechanical heart valves Novel anticoagulants in patients with mechanical heart valves | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Novel anticoagulants in patients with mechanical heart valves Article Text Therapeutics Randomised clinical trial Novel anticoagulants in patients with mechanical heart valves Ralph A H Stewart Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Eikelboom JW , Connolly SJ , Brueckmann M , et al . Dabigatran versus

Evidence-Based Medicine (Requires free registration)2014

214. Dialysis interventions for the treatment of acute kidney injury: Anticoagulation

Dialysis interventions for the treatment of acute kidney injury: Anticoagulation KHA-CARI Adaptation of KDIGO Clinical Practice Guideline for Acute Kidney Injury (May 2014) Page 1 Section 5.1 DIALYSIS INTERVENTIONS FOR THE TREATMENT OF ACUTE KIDNEY INJURY: ANTICOAGULATION Author: Bernadette B Hickey GUIDELINES a. During AKI we recommend commencing RRT using anticoagulation unless the risk is considered unacceptable. (1B) b. If a patient is receiving systemic anticoagulation, we suggest (...) that this may be sufficient for RRT. (2B) c. For anticoagulation in intermittent RRT, we recommend using either unfractionated or low-molecular weight heparin, rather than other anticoagulants. (1C). d. For anticoagulation in CRRT, we recommend using either regional citrate anticoagulation, low dose unfractionated heparin, a protocol- based heparin dose targeting a systemic APTT or a weight-based dose of low molecular weight heparin. The choice should be based on patient characteristics and local practices

KHA-CARI Guidelines2014

216. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis

Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review (...) and network meta-analysis Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, Clifford T, Gandara E, Wells G, Carrier M CRD summary This review of 12 randomised controlled trials found that oral anticoagulants (dabigatran, rivaroxaban, apixaban and vitamin K antagonists) and antiplatelet agents (acetylsalicylic acid) were associated with a reduced recurrence of venous thromboembolism compared with placebo or observation. This finding is likely to be reliable but comparisons of individual

DARE.2013

217. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial

Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial 23966309 2013 12 09 2014 07 30 2013 12 09 1522-9645 34 46 2013 Dec European heart journal Eur. Heart J. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. 3572-9 10.1093/eurheartj/eht328 Limited data are available on the impact of renal function on the outcome of patients with atrial fibrillation (AF). AMADEUS (...) was a multicentre, randomized, open-label non-inferiority study that compared fixed-dose idraparinux with conventional anticoagulation by dose-adjusted vitamin K antagonists. We performed a post hoc analysis to assess the impact of renal function on the outcomes of anticoagulated AF patients. The primary efficacy outcome was the composite of stroke/systemic embolism (SE). The principal safety outcome of this analysis was major bleeding. We calculated c-indexes, reflecting the ability for discriminating diseased

EvidenceUpdates2013

218. Anticoagulation With Otamixaban and Ischemic Events in Non-ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial.

Anticoagulation With Otamixaban and Ischemic Events in Non-ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial. IMPORTANCE: The optimal anticoagulant for patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) managed with an invasive strategy remains controversial. OBJECTIVE: To compare the clinical efficacy and safety of otamixaban, a novel intravenous direct factor Xa inhibitor, with that of unfractionated heparin plus downstream eptifibatide

JAMA2013

219. Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review

Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

NIHR HTA programme2013

220. Are We Too Hesitant to Anticoagulate Elderly Patients with Atrial Fibrillation? A Risk-Benefit Analysis

Are We Too Hesitant to Anticoagulate Elderly Patients with Atrial Fibrillation? A Risk-Benefit Analysis Are We Too Hesitant to Anticoagulate Elderly Patients with Atrial Fibrillation? A Risk-Benefit Analysis | Clinical Correlations Are We Too Hesitant to Anticoagulate Elderly Patients with Atrial Fibrillation? A Risk-Benefit Analysis June 28, 2013 By Sunny N. Shah, MD Faculty Peer Reviewed Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia and its prevalence increases (...) which is increased by greater than five-fold in patients with . (8) Given these results, the current American Heart Association/American College of Cardiology/European Society of Cardiology guidelines for the management of AF recommend the use of anticoagulation based on a patient’s risk of ischemic stroke. This risk is determined using known risk factors such as those identified by the CHA2DS2-VASc scoring system. (9) These guidelines thus give a Class IA recommendation to the statement

Clinical Correlations2013